STOK Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
11.3M
+20.7%
9.3M
+49.7%
6.2M
+344.3%
1.4M
-86.8%
10.6M
Cost of Revenue
0
0
0
0
0
Gross Profit
11.3M
+20.7%
9.3M
+49.7%
6.2M
+344.3%
1.4M
-86.8%
10.6M
Operating Expenses
88.6M
+18.5%
74.8M
+25.3%
59.6M
-5.1%
62.8M
+17.0%
53.7M
R&D
59.8M
+20.9%
49.5M
+24.8%
39.7M
-4.8%
41.7M
+10.6%
37.7M
SG&A
28.7M
+13.8%
25.3M
+26.4%
20.0M
-5.5%
21.1M
+31.9%
16.0M
Operating Income
-77315000
-18.2%
-65429000
-22.5%
-53418000
+13.1%
-61439000
-42.6%
-43091000
EBITDA
-76860000
-17.5%
-65429000
-23.5%
-52979000
+13.2%
-61034000
-43.1%
-42649000
Net Income
-73644000
-19.5%
-61618000
-23.2%
-50003000
+13.7%
-57934000
-51.1%
-38347000
EPS (Basic)
$-1.08
-16.1%
$-0.93
-17.7%
$-0.79
+15.1%
$-0.93
-43.1%
$-0.65
EPS (Diluted)
$-1.08
-16.1%
$-0.93
-17.7%
$-0.79
+17.7%
$-0.96
-47.7%
$-0.65
Shares (Diluted)
68.4M
+3.6%
66.0M
+4.7%
63.1M
+4.2%
60.5M
+3.2%
58.6M
Stoke Therapeutics (STOK) — Financials